Stockreport

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 [Yahoo! Finance]

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF Preclinical safety, efficacy, and pharmacokinetics support MP0621's potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic [Read more]